Filament Health’s Strategic Move: Transitioning from OTCQB to OTC Pink Limited for Enhanced Growth and Opportunities

Filament Health Corp., based in Vancouver, is a company focused on developing natural psychedelic medicines. As of May 28, 2025, the company will move its stock listing from the OTCQB Venture Market to the OTC Pink Limited Information tier. They’re also ending their listing on the Frankfurt Stock Exchange.

This change follows the company’s decision to drop off the Cboe Canada Exchange. The main reason? Low trading volume and a desire to cut costs. Filament is dedicated to advancing its clinical research and aims to make safe, natural psychedelics accessible to those who need them.

Despite these transitions, Filament promises to keep shareholders informed. They will continue to meet their reporting obligations and keep data updated on the OTC Markets platform.

Insights on Psychedelic Medicine

The field of psychedelic medicine is gaining traction. Recent studies suggest that psychedelics can help treat mental health issues like depression and PTSD. For example, a survey by the American Psychological Association revealed that nearly 60% of Americans believe psychedelics should be legalized for medical use. This growing public support is crucial as companies like Filament work to bring new treatments to market.

Experts weigh in on the importance of this shift. Dr. Johns Hopkins, a leading figure in psychedelic research, states, “The psychological benefits of psychedelics can’t be ignored. They hold promise for conditions that haven’t responded to traditional therapies.”

Historically, psychedelics were heavily stigmatized and classified as dangerous. However, a rising body of research is changing perceptions. A 2023 report from the Multidisciplinary Association for Psychedelic Studies (MAPS) revealed that over 72% of participants in studies experienced significant improvements in their conditions.

In the social media space, discussions about psychedelics are buzzing. Hashtags like #PsychedelicMedicine are frequently trending as users share personal stories of recovery and healing. This reflects a shift toward acceptance and understanding, offering hope to many.

Filament Health’s commitment to developing these medicines could not only shape the future of mental health treatment but also change how society views psychedelics. The journey is just beginning, but its potential impact is undeniable.

For more information about Filament Health, visit their website here.

Source link

Frankfurt Stock Exchange, drug development, Filament Health Corp, OTCQB, natural psychedelics, Cboe Canada Exchange, Filament, psychedelic drug